Last reviewed · How we verify

Morphine plus Ketamine

University of California, San Francisco · Phase 3 active Small molecule

Morphine and ketamine together provide analgesia through complementary pathways: morphine acts as an opioid receptor agonist while ketamine blocks NMDA receptors, potentially reducing opioid tolerance and enhancing pain relief.

Morphine and ketamine together provide analgesia through complementary pathways: morphine acts as an opioid receptor agonist while ketamine blocks NMDA receptors, potentially reducing opioid tolerance and enhancing pain relief. Used for Moderate to severe pain (phase 3 indication under investigation).

At a glance

Generic nameMorphine plus Ketamine
SponsorUniversity of California, San Francisco
Drug classOpioid analgesic combined with NMDA receptor antagonist
TargetMu-opioid receptor (morphine); NMDA receptor (ketamine)
ModalitySmall molecule
Therapeutic areaPain Management
PhasePhase 3

Mechanism of action

Morphine binds to mu-opioid receptors to reduce pain perception and emotional response to pain. Ketamine antagonizes NMDA glutamate receptors, which are involved in pain signal amplification and opioid tolerance development. The combination may allow lower opioid doses while maintaining or improving analgesia and potentially reducing adverse effects associated with high-dose opioid monotherapy.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: